In May 1989, a 43-year-old woman with chronic myelocytic leukemia diagnosed in 1988 underwent a syngeneic bone marrow transplant (BMT), conditioned with cyclophosphamide-TBI while in chronic phase. Three years later, because of both cytogenetic and hematological relapse, she was treated with interferon-␣ (IFN-␣) and hydroxyurea (HU) for 3 years. In 1994 while still in chronic phase, she was conditioned with busulfan-cyclophosphamide (BU-CY) and underwent a second syngeneic BMT. In 1996, following a further cytogenetic and hematological relapse, she was again placed on IFN-␣ and HU therapy for 13 months, when she was referred to our hospital in accelerated phase. In October 1997 following thiotepa, CY and anti-thymocyte globulin conditioning, she underwent an allogeneic BMT from her 1-Ag mismatched brother. She became Ph1 negative with full chimerism and normal hematological parameters; acute graft-versus-host disease (GVHD) grade 3 of the skin and chronic GVHD of the liver occurred. At 11 months follow-up she is in good clinical condition and with a Karnofsky score of 90%. The role of a graft-versus-leukemia (GVL) effect in securing and maintaining the complete remission is discussed. Keywords: chronic myeloid leukemia; graft-versusleukemia Allogeneic bone marrow transplantation (BMT) is the only curative treatment for chronic myeloid leukemia (CML), 1 even though the leukemic clone may not always be eradicated by the preparative regimen. Therefore, an alloreactive T cell-mediated GVL effect is considered important in controlling the leukemic clone, thus preventing relapse.
1
even though the leukemic clone may not always be eradicated by the preparative regimen. Therefore, an alloreactive T cell-mediated GVL effect is considered important in controlling the leukemic clone, thus preventing relapse. 2, 3 A GVL effect was initially postulated on the basis of the lower rate of leukemia relapse in patients with GVHD. marrow, advanced disease phase at the time of transplant and failure to develop GVHD. 2, 3 The strongest evidence supporting the concept of GVL is the observation that patients with CML who relapse after allogeneic BMT can obtain a 2nd CR following infusion of donor lymphocytes.
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Case report
A 43-year-old woman was diagnosed with Ph1 positive CML in chronic phase in 1988 in another hospital. In May 1989, she underwent a syngeneic BMT in the same institution, conditioned with the CY-TBI regimen. In May 1991, cytogenetic and hematologic relapse occurred, treated with interferon-␣ (IFN-␣). In November 1994, while still in chronic phase (CP), a second syngeneic BMT was performed. On this occasion, the patient was conditioned with the Bu-Cy (16-100) regimen. Two years later, in July 1996, a further relapse occurred and a second cycle of therapy with IFN-␣ and HU was initiated; no information on bcrabl rearrangement during this period is available. The patient came to our attention in August 1997, in accelerated phase, with thrombocytopenia, splenomegaly, additional karyotypic abnormalities and 30% of myeloblasts in the bone marrow smear.
We offered the patient an allogeneic BMT from her brother who was 1-Ag mismatched at locus A. The donor was treated with G-CSF, 10 g/kg the day before bone marrow harvest. The patient was conditioned for BMT with therapy, which included thiotepa 15 mg/kg, cytoxan 150 mg/kg, antithymocyte globulin 1. vial/10 kg/day for 4 days. Infection prophylaxis included low-dose amphotericin (0.1 mg/kg) and ciprofloxacin 500 mg twice daily. GVHD prophylaxis was cyclosporin A from day Ϫ7 and short course methotrexate. She also received foscarnet until day ϩ100 as prophylaxis against cytomegalovirus reactivation.
Full engraftment was observed at day ϩ17 together with the onset of skin GVHD, grade III, successfully treated with steroids.
The karyotype, performed on day ϩ21 showed complete chimerism, with an XY karyotype. At day ϩ113 elevated levels of GOT/GPT, AP and gamma-GT were found. Liver biopsy was consistent with GVHD and the patient was treated with steroids, gradually tapered. Her karyotype, performed monthly, was always XY Ph-negative; bcr/abl rearrangement checked at ϩ210 post-BMT was negative.
The patient is now on low dosage steroid treatment (cyclosporin A has never been discontinued) for limited cGVHD, 13 months after BMT in good clinical condition (Karnofsky score, 90).
Discussion
Allogeneic bone marrow transplantation is currently considered the only curative therapy for CML. 1 However, relapse post-BMT is still a major obstacle, occurring in 16-20% of patients transplanted with fully matched siblings in chronic phase. 1, 5 Relapse incidence is much higher in patients who receive T cell-depleted marrow 2 and syngeneic BMT, 9 while it is particularly low following both matched unrelated donor (10%) and mismatched unrelated donor (3-4%) transplants. [10] [11] [12] The protective effect of aGVHD and especially cGVHD in preventing relapse suggests that GVL is more important than chemoradiotherapy in the eradication of the leukemic clone. Moreover, many authors have recently reported the successful treatment of CML relapse after BMT with donor leukocyte infusions, [5] [6] [7] [8] confirming the GVL effect obtained with this procedure.
The outcome of our case is in keeping with the data reported above: despite the relatively short follow-up (13 months) we feel entitled to ascribe the eradication of the accelerated phase of CML mainly to a graft-versus-leukemia effect, since the patient had relapsed twice after two subsequent myeloablative regimens.
The second consideration is the number of transplants: to our knowledge no case involving three successive transplants has been reported to date. However, it should be noted that our case is singular in that an allogeneic BMT was performed after two prior syngeneic BMTs. All the reports in the literature [13] [14] [15] [16] deal with a second transplant performed for post-transplant leukemia relapse and all of them confirm the high treatment-related mortality after 2nd BMT.
The largest study 16 (reported by the EBMT Leukemia Working Party) analyses the data obtained from 90 2nd BMTs carried out for relapsed leukemia: the disease-free survival is 11% at 3 years and continuing remission is favored by cGVHD occurring after the 2nd BMT. It is noteworthy that among the 13 patients surviving disease-free for more than 2 years, only one CML patient had a 2nd BMT from an HLA-matched sibling following the first from an identical twin.
